tiprankstipranks
Advertisement
Advertisement

JP:2160 Stock Latest News

GNI Group Issues Revenue-Only Forecast for 2026 Amid Regulatory Uncertainty
Company AnnouncementsGNI Group Issues Revenue-Only Forecast for 2026 Amid Regulatory Uncertainty
8d ago
GNI Group Maintains Core Leadership, Adds New Outside Director After AGM
PremiumCompany Announcements
GNI Group Maintains Core Leadership, Adds New Outside Director After AGM
14d ago
GNI Group Showcases Leadership in Fibrosis Therapies With Key China Designations
PremiumCompany Announcements
GNI Group Showcases Leadership in Fibrosis Therapies With Key China Designations
15d ago
GNI Group Moves Closer to Commercialization With China NDA for Liver Fibrosis Drug F351
PremiumCompany Announcements
GNI Group Moves Closer to Commercialization With China NDA for Liver Fibrosis Drug F351
17d ago
GNI Group Wins Priority Review in China for Hepatitis B–Related Liver Fibrosis Drug
PremiumCompany Announcements
GNI Group Wins Priority Review in China for Hepatitis B–Related Liver Fibrosis Drug
23d ago
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen
PremiumCompany AnnouncementsGNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen
28d ago
GNI Group Revises Parent-Only Results After Tax and Valuation Adjustments
Premium
Company Announcements
GNI Group Revises Parent-Only Results After Tax and Valuation Adjustments
1M ago
GNI Group Revamps Board Slate With New Independent Director Ahead of AGM
Premium
Company Announcements
GNI Group Revamps Board Slate With New Independent Director Ahead of AGM
1M ago
GNI Group Revises FY2025 Results After Overstated CFC Tax Expense
PremiumCompany Announcements
GNI Group Revises FY2025 Results After Overstated CFC Tax Expense
1M ago
GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal
PremiumCompany Announcements
GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal
1M ago
GNI Group Swings to Non-Consolidated Loss on Absence of One-Off Gain and Forward Transaction Hit
PremiumCompany Announcements
GNI Group Swings to Non-Consolidated Loss on Absence of One-Off Gain and Forward Transaction Hit
2M ago
GNI Group Swings to Loss in FY2025 Despite Higher Revenue and Stronger Equity Base
PremiumCompany Announcements
GNI Group Swings to Loss in FY2025 Despite Higher Revenue and Stronger Equity Base
2M ago
GNI Group Delays 2026 Earnings Forecast Amid Regulatory and Pipeline Uncertainty
PremiumCompany AnnouncementsGNI Group Delays 2026 Earnings Forecast Amid Regulatory and Pipeline Uncertainty
2M ago
GNI Group Explains Acquisition Plans, Earnings Revision and F351 Disclosure Strategy
Premium
Company Announcements
GNI Group Explains Acquisition Plans, Earnings Revision and F351 Disclosure Strategy
2M ago
3G6 Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
3G6 Earnings this Week: How Will it Perform?
2M ago
GNI Group Slashes 2025 Profit Outlook as Cullgen Listing Is Delayed and Impairment Losses Loom
PremiumCompany Announcements
GNI Group Slashes 2025 Profit Outlook as Cullgen Listing Is Delayed and Impairment Losses Loom
3M ago
GNI Group Makes Dental Lab ZOO LABO a Consolidated Subsidiary to Bolster Japan Medtech Base
PremiumCompany Announcements
GNI Group Makes Dental Lab ZOO LABO a Consolidated Subsidiary to Bolster Japan Medtech Base
3M ago
GNI Subsidiary Cullgen to Showcase Advancing Pipeline at J.P. Morgan Healthcare Conference
PremiumCompany Announcements
GNI Subsidiary Cullgen to Showcase Advancing Pipeline at J.P. Morgan Healthcare Conference
3M ago
GNI Group’s F351 Secures Path Toward Conditional Approval and Priority Review in China
PremiumCompany Announcements
GNI Group’s F351 Secures Path Toward Conditional Approval and Priority Review in China
3M ago
GNI Group Exits Governance Partners ASIA Fund and Brings Key Holding On-Balance Sheet
PremiumCompany AnnouncementsGNI Group Exits Governance Partners ASIA Fund and Brings Key Holding On-Balance Sheet
4M ago
GNI Subsidiary Cullgen and Pulmatrix Relax Merger Terms to Seek Strategic Alternatives
Premium
Company Announcements
GNI Subsidiary Cullgen and Pulmatrix Relax Merger Terms to Seek Strategic Alternatives
4M ago
GNI Group’s Subsidiary Reports Positive Phase 1 Trial Results for Non-Opioid Pain Treatment
Premium
Company Announcements
GNI Group’s Subsidiary Reports Positive Phase 1 Trial Results for Non-Opioid Pain Treatment
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >